Table 1.
Demographic and clinical characteristics including susceptibility factors in 30 patients with porphyria cutanea tarda treated by phlebotomy or low-dose hydroxychloroquine who achieved remission and in the 17 who were randomized to treatment.
| Characteristics | All patients | P | Randomized patients | P | ||
|---|---|---|---|---|---|---|
| Phlebotomy (N=17) |
Hydroxychloroquine (N=13) |
Phlebotomy (N=7) |
Hydroxychloroquine (N=10) |
|||
| Age (Years, mean±SD) | 51.3±5.0 | 50.3±6.0 | 0.61 | 50.7±5.4 | 49±6.3 | 0.66 |
| Sex (% males) | 88 | 38 | 0.004 | 86 | 30 | 0.024 |
| Race (% Caucasians) | 94 | 92 | 0.84 | 86 | 90 | 0.78 |
| Alcohol use* (% of cases) | 100 | 92 | 0.24 | 100 | 90 | 0.39 |
| Smoking* (% of cases) | 88 | 92 | 0.71 | 86 | 90 | 0.79 |
| Estrogen use* (% of cases) | 0 | 46 | 0.002 | 0 | 50 | 0.026 |
| Hepatitis C (% of cases) | 88 | 92 | 0.71 | 100 | 90 | 0.39 |
| HIV (% of cases) | 0 | 0 | NA | 0 | 0 | NA |
| HFE mutations (% of cases) | 58 | 77 | 0.30 | 43 | 70 | 0.26 |
| UROD mutations (% of cases) | 6 | 8 | 0.84 | 14 | 10 | 0.79 |
| No. of prior PCT episodes (mean±SD) | 0.47±0.80 | 0.54±0.88 | 0.83 | 0.43±0.92 | 0.5±0.85 | 0.85 |
| Current episode in mo (mean±SD) | 12±4 | 27±10 | 0.14 | 13±5 | 32±13 | 0.28 |
| Ferritin† (nmol/ml, mean±SD, range) |
482±272 101–1251 |
311±200 113–858 |
0.07 | 344±159 101–579 |
334±221 113–858 |
0.91 |
| Plasma Porphyrins† (mcg/dL, mean±SD (range) |
7.2±6.4 1.5–25.6 |
7.8±7.2 1.1–25.5 |
0.78 | 4.6±2.7 1.5–8.2 |
8.2±7.9 1.1–25.5 |
0.27 |
| Urine porphyrins† (nmol/L, mean±SD (range) |
1958±2484 310–10,317 |
2509±2801 471–9703 |
0.57 | 1451±1173 347–3336 |
2963±3064 471–9703 |
0.24 |
Abbreviations: HFE, hemochromatosis gene; UROD, uroporphyrinogen decarboxlase.
*
Within the previous year
†
Pretreatment